key: cord-0831959-i7yul1c1 authors: Walsh, Mary Norine; Sorgente, Antonio; Fischman, David L.; Bates, Eric R.; Grapsa, Julia title: COVID-19 pandemic and cardiovascular complications: what have we learned so far? date: 2020-06-15 journal: JACC Case Rep DOI: 10.1016/j.jaccas.2020.06.017 sha: 866e55a4e9ec2a3e990c103aa04c9218f184ee90 doc_id: 831959 cord_uid: i7yul1c1 nan The COVID-19 pandemic has revolutionized clinical practice in the last months unlike any other health emergency in recent years. JACC: Case Reports has taken this challenge very seriously, dedicating to it an entire issue. We received wonderful cases from across the world. Our goal is to provide a comprehensive report of representative cardiovascular involvement in COVID-19 ( Figure 1 ). Besides the concern about QT-interval prolongation with hydroxychloroquine and azithromycin treatment, COVID-19 is strongly associated with the occurrence of sudden unexpected arrhythmias. Given the general ignorance on the pathophysiological mechanisms of the virus at the time of submission of these case reports, it is hard to state with certainty that COVID-19 has been the cause of these arrhythmias, but they surely give interesting direction for future research in the field. Included are cases of Brugada type I pattern positivization (1) in the context of fever, one of the most common presenting symptoms of the disease (2); electrical ventricular storm (3), transient AV block in the absence of myocarditis (4) , sinus node dysfunction requiring pacemaker implantation(5), and finally a provocative case on the use of amiodarone as a possible treatment for COVID-19 (6) . Overall, the cytokine storm proved to have a strong impact on the conduction system. The clinical presentation of patients with COVID-19 has ranged from asymptomatic to ARDS requiring mechanical ventilation. One cause of sudden respiratory deterioration is the increased risk for venous thromboembolic disease in these patients (7, Figure 2 ). These events have been noted both early and in the recovery phase of COVID-19. Furthermore, the thromboembolic events have occurred despite the use of prophylactic anticoagulation or even full anticoagulation (8) . A majority of patients have elevated levels of d-dimer and laboratory findings consistent with sepsis-induced diffuse intravascular coagulation, suggesting a coagulopathic process, yet no prospective studies have demonstrated the predictive nature of these markers for the occurrence of a thromboembolic event, only a higher risk of mortality (9) . The early recognition and treatment of venous thromboembolic disease has therefore been a dilemma. We therefore provide commentary and suggest treatment algorithms (10) . We received four general categories of case reports detailing an increased risk of arterial thrombosis during the COVID-19 pandemic. First, the decreased rate of acute hospitalization for STEMI has paralleled an increased incidence of patients presenting late after STEMI onset. The result has been to remind us in several submissions of the natural history of STEMI before the reperfusion therapy era when transmural infarction was associated with severe complications. These include complete atrioventricular heart block, left ventricular aneurysm formation, left ventricular apical thrombosis with risk for systemic embolization, severe ischemic cardiomyopathy, rupture of the left ventricular free wall or intraventricular septum, papillary muscle ischemia or rupture, and left or right ventricular shock. Another report suggested an increased risk for coronary stent thrombosis (Figure 3) causing STEMI in infected patients (11, 12) . Second, there were a number of cases of STEMI in patients under the age of 30 years without risk factors for atherosclerosis (13) . This phenomenon occasionally occurred before COVID-19, but this increased incidence reminds us to always remember myocardial infarction in the differential diagnosis of a younger patient with chest pain and to always consider performing a screening EKG. Third, a number of cases of STEMI mimics were submitted including patients with ST-segment elevation due to myopericarditis, Brugada pattern, Takotsubo cardiomyopathy, or endothelial dysfunction due to infection or cytokine storm. As many as 40% of patients with COVID-19 and ST-segment elevation may have normal coronary arteries on angiography, complicating the decision whether to administer fibrinolytic therapy to patients without early access to primary PCI. Finally, there were reports of spontaneous thrombosis (14) involving the ascending and descending aorta, the cerebrovascular arteries, the mesenteric and renal arteries, and the peripheral arteries, underscoring an increased systemic risk of arterial thrombosis in patients with COVID-19. The development of heart failure in patients infected with the SARS-CoV-2 virus has been described to involve two different, and overlapping, mechanisms. One is cytokine release resulting in myocardial inflammation ( Figure 4 ) and the other is purported to be direct viral infection causing myocarditis (15) . Endomyocardial biopsy of affected patients has demonstrated both inflammatory infiltrates and viral particles. The heart failure cases presented in this special issue, however, describe more varied presentations of patients, some with pre-existing heart failure and others with no known cardiac disease prior to becoming ill with infection. In addition to cases of direct myocardial injury, some with pathological evidence, we also present two cases of Takotsubo cardiomyopathy (16, 17) without evidence of STEMI or coronary artery disease. Both patients had ventricular recovery after supportive treatment, one of whom had recently undergone cardiac transplantation. The authors of this latter report, elegantly describe the complex investigation of possible allograft rejection and the delicate balance of immunosuppression in the setting of SARS-CoV-2 infection. Two cases highlight the special circumstances faced by patients with left ventricular assist devices (LVAD) (18, 19) which include the inability to tolerate prone positioning to augment respiratory support due to the mechanical equipment, and the hypothesis that mechanical circulatory support may provide a type of protection against the most serious hemodynamic consequences of SARS-CoV-2 infection. Included also is a case series of pediatric patients who had hemodynamic collapse and cardiac dysfunction (20), a presentation that has been rare in this younger age group. The now well-recognized thromboembolic disorders encountered with this disease include a case in this issue of massive pulmonary embolism and resultant severe right heart failure (8) . And two separate cases describe patients with concomitant non-cardiac disease, one with human immunodeficiency virus (HIV) (18) and one with influenza (21) . All the cases of heart failure represent the authors' best attempts at providing supportive and emerging therapies at a time when they had no established guidelines and no best practices to follow. Importantly enough, from the beginning of the pandemic, we felt that it was very important to publish the "voices" of our front-line colleagues across the world, to help cardiologists to get acquainted with mechanical ventilation (22) , to describe the first evidence of sex differences in COVID-19 (23) , as well as discuss the significant changes in healthcare with telemedicine and virtual clinics. The impact of COVID-19 on African Americans has also recently been described in JACC (24) . Our aim was to provide a complete and comprehensive issue, in parallel knowledge with the sister JACC journals and ACC COVID Hub. Transient Brugada-like electrocardiographic pattern in a patient with COVID-19. JACC: Case Reports The known into the unknown Brugada Syndrome and COVID-19. JACC: Case Reports Electrical storm in COVID-19. JACC: Case Reports HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19) Sinus node dysfunction in a young patient with COVID-19 Safety and efficacy of amiodarone in a patient with COVID-19. JACC: Case Reports Difficulties of managing submassive and massive pulmonary embolism in the era of COVID-19. JACC: Case Reports COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC: Case Reports Thrombosis and thromboembolism related to COVID-19 increase the level of awareness, lower the threshold of suspicion, and keep following the guidelines. JACC: Case Reports Right ventricular clot in transit in COVID-19: Implications for the Pulmonary Embolism Response Team. JACC: Case Reports A case series of stent thrombosis during the COVID-19 pandemic. JACC: Case Reports COVID-19 STEMI 2020: It's not what you know, it's how you think. JACC: Case Reports Acute multi-vessel coronary occlusion revealing COVID-19 in a young adult Four cases of aortic thrombosis in patients with COVID-19 SARS-CoV-2 fulminant myocarditis Takotsubo syndrome in the setting of COVID-19 infection. JACC: Case Reports Covid-19 pneumonia, Takotsubo syndrome and left ventricle thrombi Predisposition or protection? COVID-19 in a patient on LVAD support with HIV/AIDS. JACC: Case Reports The imperfect cytokine storm: Severe COVID-19 with ARDS in patient on durable LVAD support. JACC: Case Reports Stress Induced Cardiomyopathy Precipitated by COVID-19 and Influenza A Co-Infection Reacquainting cardiology with mechanical ventilation in response to the COVID-19 pandemic. JACC: Case Reports Sex differences in mortality from COVID-19 pandemic: Are men vulnerable and women protected? JACC: Case Reports African-American COVID-19 Mortality: A Sentinel Event